Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom

被引：0
|
作者：
Parker, B. [1 ]
Chounta, V. [2 ]
Gait, C. [3 ]
Hayward, O. [4 ]
Hunjan, M. [3 ]
Schroeder, M. [2 ]
Jacob, I. [1 ]
Van de Velde, N. [2 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Hlth Econ, Cardiff, Wales
[2] ViiV Healthcare, Global Hlth Outcomes, London, England
[3] GSK, Hlth Outcomes, London, England
[4] Hlth Econ & Outcomes Res Ltd, Med Writing, Cardiff, Wales
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P030
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [41] Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine
    Hill, Lucas A.
    Abulhosn, Kari K.
    Yin, Jeffrey F.
    Bamford, Laura P.
    AIDS, 2023, 37 (04) : 605 - 609
  • [42] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
    Rizzardini, Giuliano
    Overton, Edgar T.
    Orkin, Chloe
    Swindells, Susan
    Arasteh, Keikawus
    Gorgolas Hernandez-Mora, Miguel
    Pokrovsky, Vadim
    Girard, Pierre-Marie
    Oka, Shinichi
    Andrade-Villanueva, Jaime F.
    Richmond, Gary J.
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Griffith, Sandy
    Harrington, Conn M.
    Hudson, Krischan J.
    St Clair, Marty
    Talarico, Christine L.
    Patel, Parul
    Cutrell, Amy
    Van Eygen, Veerle
    D'Amico, Ronald
    Mrus, Joseph M.
    Wu, Sterling
    Ford, Susan L.
    Chow, Ken
    Roberts, Jeremy
    Wills, Angela
    Walters, Nicola
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Smith, Kimberly Y.
    Spreen, William R.
    Margolis, David A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
  • [43] Long-Acting Cabotegravir for HIV Prevention Issues of Access, Cost, and Equity
    Sharfstein, Joshua M.
    Killelea, Amy
    Dangerfield, Derek
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (10): : 921 - 922
  • [44] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Moreno, Santiago
    Rivero, Antonio
    Ventayol, Pere
    Falco, Vicenc
    Torralba, Miguel
    Schroeder, Melanie
    Neches, Victoria
    Vallejo-Aparicio, Laura Amanda
    Mackenzie, Isaac
    Turner, Matthew
    Harrison, Cale
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) : 2039 - 2055
  • [45] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Santiago Moreno
    Antonio Rivero
    Pere Ventayol
    Vicenç Falcó
    Miguel Torralba
    Melanie Schroeder
    Victoria Neches
    Laura Amanda Vallejo-Aparicio
    Isaac Mackenzie
    Matthew Turner
    Cale Harrison
    Infectious Diseases and Therapy, 2023, 12 : 2039 - 2055
  • [46] Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy
    D'Amico, Ronald
    Gomis, Santiago Cenoz
    Moodley, Riya
    Van Solingen-Ristea, Rodica
    Baugh, Bryan
    Van Landuyt, Erika
    Van Eygen, Veerle
    Min, Sherene
    Cutrell, Amy
    Foster, Caroline
    Chilton, Daniella
    Allard, Sabine D.
    Ruiter, Annemiek
    HIV MEDICINE, 2023, 24 (02) : 202 - 211
  • [47] Perspectives of People With Human Immunodeficiency Virus on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study
    Orkin, Chloe
    Hayes, Rosalie
    Haviland, Joanne
    Wong, Yuk Lam
    Ring, Kyle
    Apea, Vanessa
    Kasadha, Bakita
    Clarke, Emily
    Byrne, Ruth
    Fox, Julie
    Barber, Tristan J.
    Clarke, Amanda
    Paparini, Sara
    ILANA study Grp, Sadna
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [48] A COST-UTILITY ANALYSIS OF LIGHTERLIFE TOTAL AS A TREATMENT FOR OBESITY IN THE UNITED KINGDOM
    Lewis, L.
    Taylor, M.
    VALUE IN HEALTH, 2013, 16 (07) : A385 - A385
  • [49] Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis
    Landovitz, Raphael J.
    Delany-Moretlwe, Sinead
    Fogel, Jessica M.
    Marzinke, Mark A.
    Piwowar-Manning, Estelle
    Richardson, Paul
    Halvas, Elias K.
    Mellors, John W.
    Persaud, Deborah
    Kofron, Ryan
    McCauley, Marybeth
    Rose, Scott
    Rinehart, Alex R.
    Rooney, James F.
    Adeyeye, Adeola
    Cohen, Myron S.
    Donnell, Deborah
    Hosseinipour, Mina C.
    Grinsztejn, Beatriz
    Eshleman, Susan H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1253 - 1256
  • [50] The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment
    Alberton, Francesca
    Nozza, Silvia
    Raccagni, Angelo Roberto
    Galli, Laura
    Spagnuolo, Vincenzo
    Bossolasco, Simona
    Cernuschi, Massimo
    Canetti, Diana
    Hasson, Hamid
    Castagna, Antonella
    Gianotti, Nicola
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
12345